Cohen Klingenstein’s Viatris VTRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$291K Hold
18,354
0.01% 199
2026
Q1
$248K Hold
18,354
0.01% 202
2025
Q4
$229K Hold
18,354
0.01% 202
2025
Q3
$182K Hold
18,354
0.01% 203
2025
Q2
$164K Hold
18,354
0.01% 203
2025
Q1
$160K Hold
18,354
0.01% 207
2024
Q4
$229K Hold
18,354
0.01% 207
2024
Q3
$213K Hold
18,354
0.01% 220
2024
Q2
$195K Sell
18,354
-457
-2% -$5.05K 0.01% 222
2024
Q1
$225K Hold
18,811
0.01% 219
2023
Q4
$204K Hold
18,811
0.01% 221
2023
Q3
$185K Sell
18,811
-122
-0.6% -$1.27K 0.01% 221
2023
Q2
$189K Hold
18,933
0.01% 221
2023
Q1
$182K Hold
18,933
0.01% 219
2022
Q4
$211K Hold
18,933
0.01% 217
2022
Q3
$161K Hold
18,933
0.01% 223
2022
Q2
$198K Hold
18,933
0.01% 222
2022
Q1
$206K Hold
18,933
0.01% 226
2021
Q4
$256K Sell
18,933
-2,130
-10% -$28.4K 0.01% 221
2021
Q3
$285K Sell
21,063
-2,009
-9% -$28.5K 0.01% 235
2021
Q2
$330K Hold
23,072
0.01% 229
2021
Q1
$322K Hold
23,072
0.01% 229
2020
Q4
$432K Buy
+23,072
New +$376K 0.02% 216

Other funds holding VTRS

Cohen Klingenstein's VTRS Position: Q2 2026 in Review

Cohen Klingenstein held its Viatris (VTRS) position steady in Q2 2026 at 18,354 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #199.

Cohen Klingenstein first reported a position in VTRS in Q4 2020 and has held it in 23 quarters since. The position peaked at $432K in Q4 2020. 386 funds tracked by Wall St. Rank hold VTRS as of Q2 2026.

  • Cohen Klingenstein held 18,354 shares of Viatris worth $291K as of Q2 2026.
  • Cohen Klingenstein left its Viatris share count unchanged in Q2 2026.
  • Viatris made up 0.01% of Cohen Klingenstein's portfolio in Q2 2026, its #199 holding.
  • Cohen Klingenstein first reported a position in Viatris in Q4 2020 and has held it in 23 quarters since.
  • Cohen Klingenstein's Viatris position peaked at $432K in Q4 2020.
  • 386 funds tracked by Wall St. Rank held Viatris as of Q2 2026.

Based on Cohen Klingenstein's 13F filing for Q2 2026, filed 15 Jul 2026.